{"id":46932,"date":"2022-08-04T14:01:38","date_gmt":"2022-08-04T12:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/"},"modified":"2022-08-04T14:01:38","modified_gmt":"2022-08-04T12:01:38","slug":"apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/","title":{"rendered":"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference"},"content":{"rendered":"<div>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live presentation and participate in one-on-one meetings. Please see additional details below:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/5\/Apnimed_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg\"><\/a><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Canaccord Genuity Global Growth Conference<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresentation:\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nThursday, August 11, 2022\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTime:\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n8:00 to 8:25 a.m. EDT in Griffin\/Robinson\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresenter:\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBarry Wohl, CBO\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nWebcast:\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcanaccord76%2Fapni%2F2445912&amp;esheet=52799783&amp;newsitemid=20220804005033&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcanaccord76%2Fapni%2F2445912&amp;index=1&amp;md5=be25397db2524ef5677bd53f936ef22b\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/wsw.com\/webcast\/canaccord76\/apni\/2445912<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nInterested parties may also access a live and archived webcast of the presentation on the \u201cEvents\u201d section of the company website at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fapnimed.com%2Fcategory%2Fevents%2F&amp;esheet=52799783&amp;newsitemid=20220804005033&amp;lan=en-US&amp;anchor=apnimed.com%2Fevents&amp;index=2&amp;md5=81afc4b7f87ceb231b0d845a0522bb3f\" rel=\"nofollow noopener\" shape=\"rect\">apnimed.com\/events<\/a>. One-on-one meetings will be taking place on Thursday, August 11, 2022. Investors should contact their CG representative to schedule.\n<\/p>\n<p>\n<b>About Apnimed<\/b>\n<\/p>\n<p>\nApnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea \u2013 patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed\u2019s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fapnimed.com%2F&amp;esheet=52799783&amp;newsitemid=20220804005033&amp;lan=en-US&amp;anchor=apnimed.com&amp;index=3&amp;md5=f45e0bc9271de9441dc5764ab4e15dab\" rel=\"nofollow noopener\" shape=\"rect\">apnimed.com<\/a> or follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fapnimed&amp;esheet=52799783&amp;newsitemid=20220804005033&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=6d1e2ebc3d915543f838d5849fb724b5\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fapnimed%2F%3FviewAsMember%3Dtrue&amp;esheet=52799783&amp;newsitemid=20220804005033&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=da4eb1f1e011a5ee08c524e54e8af2c2\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p>\n<b>About Obstructive Sleep Apnea<\/b>\n<\/p>\n<p>\nObstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 35 million Americans, though underdiagnosis continues to be a serious problem. OSA is characterized by partial or complete upper airway obstruction that occurs during sleep, which often leads to poor sleep, and in the long term, has been shown to exacerbate hypertension, diabetes, cardiovascular disease, and stroke. Additionally, OSA can impair work productivity, reduce functional ability, and lower quality of life.\n<\/p>\n<p>\nSleep-related muscular relaxation driven by the central nervous system is the key neurologic mechanism that causes OSA. In patients with OSA, a reduction in neuromuscular control of the upper airway during sleep leads to a corresponding relaxation of the upper airway dilator muscles. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but many patients are dissatisfied with these mechanical nighttime devices and fewer than half are compliant long-term, leaving a significant population untreated, undertreated and at risk.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Courtney Heath<br \/>\n<br \/>ScientPR<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x63;&#x6f;&#x75;&#x72;&#x74;&#x6e;&#x65;&#x79;&#x40;&#x73;&#x63;&#x69;&#x65;&#x6e;&#x74;&#112;&#114;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x6f;&#117;r&#x74;&#x6e;&#x65;&#121;&#64;&#x73;&#x63;&#x69;&#101;n&#x74;&#x70;&#x72;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\n<b>Investor Contact:<\/b><br \/>Wendy Gabel<br \/>\n<br \/>Kendall Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;l&#x74;&#111;&#x3a;&#119;g&#x61;b&#x65;&#108;&#x40;&#107;&#x65;&#110;d&#x61;l&#x6c;&#105;&#x72;&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#119;&#x67;a&#x62;&#x65;&#108;&#x40;k&#101;&#x6e;&#100;&#x61;l&#108;&#x69;r&#x2e;c&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-46932","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-04T12:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference\",\"datePublished\":\"2022-08-04T12:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/\"},\"wordCount\":437,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005033\\\/en\\\/775513\\\/21\\\/Apnimed_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/\",\"name\":\"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005033\\\/en\\\/775513\\\/21\\\/Apnimed_logo.jpg\",\"datePublished\":\"2022-08-04T12:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005033\\\/en\\\/775513\\\/21\\\/Apnimed_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005033\\\/en\\\/775513\\\/21\\\/Apnimed_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-04T12:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference","datePublished":"2022-08-04T12:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/"},"wordCount":437,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/","url":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/","name":"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg","datePublished":"2022-08-04T12:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220804005033\/en\/775513\/21\/Apnimed_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/apnimed-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46932"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46932\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}